FiercePharma

Teva gains FDA approval for once-daily formulation of flagship drug Austedo

Attuned to the burdens of people living with Huntington’s disease (HD) chorea and tardive dyskinesia (TD), Teva has been eager to cut the amount of pills patients need to take in half. Now, it's ...
Morningstar

Teva Earnings: Robust Gains From Austedo and Ajovy Fuel Sales Growth and Boost Margin

No-moat Teva TEVA reported second-quarter earnings that were slightly ahead of our expectations. Total sales were up 2.4% year over year, driven by strong performance from Teva’s key innovative ...
Monthly Prescribing Reference

Austedo XR, a Once-Daily Formulation of Deutetrabenazine, Gets FDA Approval

Austedo XR is a vesicular monoamine transporter 2 inhibitor. The Food and Drug Administration (FDA) has approved Austedo ® XR, a new once-daily formulation of deutetrabenazine, for the treatment of ...
Nasdaq

Teva's AUSTEDO XR Receives FDA Approval For Once-Daily Therapy At Therapeutic Doses

(RTTNews) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), said that the U.S. Food and Drug Administration has approved AUSTEDO XR as a one pill, once-daily ...
Monthly Prescribing Reference

Austedo Xr

Deutetrabenazine 6mg, 12mg, 18mg, 24mg, 30mg, 36mg, 42mg, 48mg; ext-rel tabs. Swallow whole. Take with or without food. Individualize. Initially 12mg once daily; may titrate at weekly intervals by 6mg ...
Healio

Austedo improves quality of life in older adults with tardive dyskinesia

Please provide your email address to receive an email when new articles are posted on . Austedo treatment appeared to improve involuntary movements and quality of life among older adults with tardive ...
Yahoo

Teva Pharm CEO sees $2.5 billion in revenue for Austedo drug by 2027

The logo of Teva Pharmaceutical Industries is seen during a news conference in Tel Aviv (Reuters) -Teva Pharmaceutical Industries' drug Austedo should reach sales of $2.5 billion by 2027, Chief ...
Nasdaq

Teva's AUSTEDO XR Receives FDA Approval For Movement Disorders Treatment

(RTTNews) - The U.S. Food and Drug Administration has approved AUSTEDO XR (deutetrabenazine) extended-release tablets, a new once-daily formulation indicated in adults for tardive dyskinesia and ...
Seeking Alpha

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR ® (deutetrabenazine) extended-release tablets Patients reported ...
Healio

Austedo does not improve tics in pediatric patients with Tourette syndrome

Please provide your email address to receive an email when new articles are posted on . Austedo did not efficaciously treat tics linked to Tourette syndrome in children and adolescents, according to ...
Yahoo Finance

Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR

INGREZZA showed a nearly two-fold higher VMAT2 occupancy, consistent with greater potency when compared to AUSTEDO XR (deutetrabenazine) after a single dose of each treatment VMAT2 occupancy is a key ...